Daniel Cohen
Co-founder, Chief Executive Officer

More than 30 years' experience in academia, biotech and big pharma companies. Professor of Medical Genetics, founder of modern genetics, genomics and pharmacogenomics. Former CSO of Genset (acquired by Serono) and VP Genetics Worldwide of Serono Genetics Institute. Co-founder of Millennium Pharma, Genethon and the CEPH research institute. Author of 150 peer-reviewed publications.

Serguei Nabirotchkin
Co-founder, Chief Biology Officer

Specialist in experimental genetics, cell signaling and systems biology. Graduated from the Moscow State University, former leader scientist at the Institute of Molecular Biology in Moscow (Russia), DKFZ (Germany), Gustave Roussy Institute (France) and Genset (France). Former Director of the Animal Model Department at the Serono Genetics Institute.

Peter Collum
Chief Financial Officer and Chief Business Officer

More than 22 years of experience within the pharmaceutical industry, with 17 of those years in healthcare investment banking focused on M&A, financing and business development transactions for public and private life sciences companies both in the US and abroad. Previously a Partner at MTS Health Partners, and prior to MTS was a Director in the healthcare investment banking group at Bank of America. Began career at Roche as an engineer.

Xavier Paoli
VP, Chief Commercial Officer

Held various marketing positions in biotech and big pharma companies (GlaxoSmithKline, UCB Pharma, Alexion). Brings 15 years of experience in the commercialization of innovative drugs notably for rare diseases. Graduated from HEC Paris with a Master of Marketing and from the University Paris 7 with Masters of Science in Genetics and Immunology.

 

Susanne Dorn
Chief Regulatory Officer

International Regulatory Affairs Strategist with 30 years’ experience in pharma and biotech industry. Previously responsible for regulatory development and product approval and maintenance in multiple therapeutic areas at Novartis, Pfizer, Amylin Pharmaceuticals, Halozyme Therapeutics and Sanofi. Experienced in the development of small molecules, biologics and gene therapy products.

Rodolphe Hajj
Chief Pharmacology Officer

More than 15 years' experience in fundamental research and drug discovery & development in stem cells, respiratory research, cystic fibrosis, cancer and neurology in academia and industry. He was in charge of the Cancer Stem Cell project at Sanofi, then led at Servier the High Content Cellular imaging platform for different disease areas.

viviane Bertrand
Chief Preclinical Drug Development Officer

Over 25 years of experience in the management and lead of R&D projects (non-clinical / clinical / CMC) in an international hospital-university context and the pharmaceutical industry. Expertise in the development of new chemical entities in major therapeutic areas: inflammation, type 2 diabetes and oncology at Lafon, Servier and Cephalon.